May 8 |
Clene GAAP EPS of -$0.09
|
May 8 |
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
|
May 1 |
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
|
Apr 23 |
Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
|
Apr 16 |
Clene stock rallies 52% post-market on MS drug data
|
Apr 16 |
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
|
Mar 19 |
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
|
Mar 15 |
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
|
Mar 7 |
Clene to Present at the 36th Annual ROTH Conference
|
Feb 29 |
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
|